GH Research publishes corporate presentation on ultra-rapid, durable remission data for TRD treatment GH001
GHRS•Cash position and development timeline
Cash, cash equivalents, and marketable securities totaled $362.7 million as of June 30, 2026; Phase 3 initiation targeted in 2026.
Corporate presentation highlights Phase 2b data for GH001
GH Research highlighted Phase 2b data for GH001, an inhaled mebufotenin candidate for treatment-resistant depression.
- Primary endpoint showed a least-squares mean MADRS change difference of -15.5 versus placebo on Day 8 (P<0.0001); Cohen’s d -2.
- Remission (MADRS ≤10) reached 57.5% on Day 8; open-label extension completers showed 73% remission at 6 months.
- Presentation emphasized an ~11-minute median psychoactive phase, positioning GH001 for a Spravato-compatible outpatient clinic workflow.
